Abstract
Background
The pathogenesis of chronic obstructive pulmonary disease (COPD) is associated with dyslipidemia, an established co-morbidity. Statins treat hypercholesterolemia, but more recently have been trailed in the setting of COPD for their potential anti-inflammatory benefits. The outcomes of prospective trials however have been inconsistent. Thus, we hypothesize that the variation in results may have been due to statin-induced downregulation of ATP-binding cassette transporter A1 (ABCA1), thereby reducing cholesterol export. This study aims to elucidate whether statin treatment in a cellular model of COPD leads to a decrease in ABCA1 protein expression.
Methods
To mimic the inflammatory environment of COPD, two commonly used lung epithelial cell lines (BEAS-2B and A549) were treated with tumor necrosis factor (TNF), and co-treated with cholesterol/25-hydroxycholesterol (25-OH) to mimic dyslipidemia. ABCA1 protein was detected by Western Blotting.
Results
We unexpectedly showed that statins did not affect ABCA1 expression. However, the LXR agonist T0901317 significantly increased ABCA1 expression in both cell lines, while TNF, cholesterol or 25-OH induced ABCA1 protein upregulation in BEAS-2B cells, indicating cell line differences in response. There was also evidence of synergistic impacts of combined treatments on ABCA1 upregulation in BEAS-2B cells.
Conclusion
Statins did not have an impact on ABCA1 expression in lung epithelial cell lines, disproving our original hypothesis. However, we showed for the first time, the effect of the inflammatory cytokine TNF, cholesterol/25-OH, statins and the LXR agonist T0901317 on expression of ABCA1 transporter protein in human lung epithelial cell lines in vitro. We hope that these in vitro studies may prove beneficial for addressing dyslipidemia in COPD in the future.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest 2013;143:798–807.
Reed RM, Iacono A, DeFilippis A, Eberlein M, Girgis RE, Jones S. Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J Heart Lung Transplant 2011;30:674–8.
Zafirova-Ivanovska B, Stojkovikj J, Dokikj D, Anastasova S, Debresliovska A, Zejnel S, et al. The level of cholesterol in COPD patients with severe and very severe stage of the disease. Open Access Macedonian J Med Sci 2016;4:277–82.
Sugiura H, Koarai A, Ichikawa T, Minakata Y, Matsunaga K, Hirano T, et al. Increased 25-hydroxycholesterol concentrations in the lungs of patients with chronic obstructive pulmonary disease. Respirology 2012;17:533–40.
Bradbury P, Traini D, Ammit AJ, Young PM, Ong HX. Repurposing of statins via inhalation to treat lung inflammatory conditions. Adv Drug Deliv Rev 2018;133:93–106.
So JY, Dhungana S, Beros JJ, Criner GJ. Statins in the treatment of COPD and asthma—where do we stand? Curr Opin Pharmacol 2018;40:26–33.
Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. New Eng J Med 2014;370:2201–10.
Young RP, Hopkins RJ, Agusti A. Statins as adjunct therapy in COPD: how do we cope after STATCOPE? Thorax 2014;69:891.
Wong J, Quinn Carmel M, Brown Andrew J. Statins inhibit synthesis of an oxysterol ligand for the liver X receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol 2004;24:2365–71.
Wong J, Quinn CM, Gelissen IC, Jessup W, Brown AJ. The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis 2008; 196:180-9.
Niesor EJ, Schwartz GG, Perez A, Stauffer A, Durrwell A, Bucklar-Suchankova G, et al. Statin-induced decrease in ATP-binding cassette transporter Al expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. Cardiovasc Drugs Ther 2015;29:7–14.
Chai AB, Ammit AJ, Gelissen IC. Examining the role of ABC lipid transporters in pulmonary lipid homeostasis and inflammation. Respiratory Res 2017;18:41.
Bates SR, Tao J-Q, Collins HL, Francone OL, Rothblat GH. Pulmonary abnormalities due to ABCA1 deficiency in mice. Am J Physiol Lung Cell Mol Physiol 2005;289: L980–L9.
Dai C, Yao X, Vaisman B, Brenner T, Meyer KS, Gao M, et al. ATP-binding cassette transporter 1 attenuates ovalbumin-induced neutrophilic airway inflammation. Am J Respir Cell Mol Biol 2014;51:626–36.
Jubinville É, Talbot M, Bérubé J-C, Hamel-Auger M, Maranda-Robitaille M, Beaulieu M-J, et al. Interplay between cigarette smoking and pulmonary reverse lipid transport. Eur Respir J 2017;50:1700681.
Sonett J, Goldklang M, Sklepkiewicz P, Gerber A, Trischler J, Zelonina T, et al. A critical role for ABC transporters in persistent lung inflammation in the development of emphysema after smoke exposure. FASEB J 2018 fj201701381.
Aguiar JA, Tamminga A, Lobb B, Huff RD, Nguyen JP, Kim Y, et al. The impact of cigarette smoke exposure, COPD, or asthma status on ABC transporter gene expression in human airway epithelial cells. Sci Rep 2019;9:153.
Fessier MB. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease. Pharmacol Ther 2018;181:1–12.
Jubinville E, Routhier J, Maranda-Robitaille M, Pineault M, Milad N, Talbot M, et al. Pharmacological activation of Liver X Receptor during cigarette smoke exposure adversely affects alveolar macrophages and pulmonary surfactant homeostasis. Am J Physiol Lung Cell Mol Physiol 2019.
Yang A, Gelissen IC. ABC-transporter mediated sterol export from cells using radiolabeled sterols. Methods Mol Biol 2017;1583:275–85.
Field FJ, Watt K, Mathur SN. TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2. J Lipid Res 2010;51:1407–15.
Edgel KA, Leboeuf RC, Oram JF. Tumor necrosis factor-alpha and lymphotoxin-alpha increase macrophage ABCA1 by gene expression and protein stabilization via different receptors. Atherosclerosis 2010;209:387–92.
Korhonen JT, Olkkonen VM, Lahesmaa R, Puolakkainen M. ABC-cassette transporter 1 (ABCA1) expression in epithelial cells in Chlamydia pneumoniae infection. Microb Pathog 2013;6(1-62-1):62–57.
Chen JH, Zheng YL, Xu CQ, Gu LZ, Ding ZL, Qin L, et al. Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1. Biol Chem 2017;398:785–92.
Hu X, Fu Y, Lu X, Zhang Z, Zhang W, Cao Y, et al. Protective effects of platycodin D on lipopolysaccharide-induced acute lung injury by activating LXRα-ABCA1 signaling pathway. Front Immunol 2017;7:.
Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009;179:35–40.
Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
He, P., Smith, A., Gelissen, I.C. et al. The effect of statins and the synthetic LXR agonist T0901317 on expression of ABCA1 transporter protein in human lung epithelial cell lines in vitro. Pharmacol. Rep 71, 1219–1226 (2019). https://doi.org/10.1016/j.pharep.2019.08.006
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2019.08.006